1. Introduction {#s0005}
===============

Inherited retinal diseases affect millions of individuals worldwide. They include many different types with more than 238 causative genes identified up to date (RetNet: <https://sph.uth.edu/retnet/> July 2015). Significant achievements have been made in the elucidation of the genetic causes of retinal diseases and mutation screening strategies have improved dramatically during the past two decades ([@bb0320]). However it is still difficult to clarify the pathophysiologic mechanisms associated with specific genotypes due to the nature of the tissue that needs to be studied. Types of retinal diseases include retinitis pigmentosa, Stargardt\'s Disease and cone dystrophies ([@bb0030]).

Retinitis pigmentosa (RP) accounts for one half of inherited retinal diseases. RP is a progressive, degenerative disease of the retina with clinical hallmarks which include night blindness, loss of peripheral vision and subsequent loss of central vision. Clinical examination reveals 'bone spicule' pigmentary deposits, retinal vessel attenuation and characteristic electroretinogram patterns. More than 3100 mutations, in more than 50 genes, cause nonsyndromic RP. In addition to genetic and mutational heterogeneity, there is extreme variation in clinical phenotypes as well as overlapping clinical symptoms ([@bb0065]).

Stargardt\'s disease 1 (STGD1, OMIM\# [248200](248200){#ir0080}) is one of the most frequent types of inherited macular dystrophy in childhood. Clinical features include degeneration of cones in the macula which begins within the first two decades of life. The disease can be inherited in an autosomal recessive fashion and it is caused by mutations in the ATP-binding cassette subfamily A group 4 (*ABCA4*) gene (OMIM\# [601691](601691){#ir0085}) which contains 50 exons and spans over 100 kb ([@bb0020], [@bb0010]). ABCA4 is a large transmembrane protein, expressed in retinal photoreceptors and localized to the outer segments disk membrane of rods, acting as a retinoid flipase involved in all-trans-retinal transport ([@bb0280], [@bb0210]). Mutations in *ABCA4* gene lead to abnormal protein and to accumulation of high levels of lipofuscin in the retinal pigment epithelium cells.

Mutations in *ABCA4* have also been associated with other forms of retinal dystrophies, such as autosomal recessive RP (arRP) and autosomal recessive cone-rod dystrophy (CORD), as well as age-related macular degeneration. These forms are characterized as *ABCA4*- associated retinopathies ([@bb0140], [@bb0060], [@bb0200], [@bb0015], [@bb0070], [@bb0195], [@bb0120], [@bb0250]). With the use of improved tools in routine laboratory diagnostics, such as *ABCA4* microarray mutation screening and next-generation sequencing, more than 800 mutations in *ABCA4* have been reported, highlighting extreme allelic heterogeneity (HGMD Professional; <http://www.biobase-international.com/product/hgmd>) ([@bb0325], [@bb0130], [@bb0085], [@bb0335]). Carrier frequency of *ABCA4* varies significantly between different populations. Many variants are common in specific geographic and ethnic groups ([@bb0200], [@bb0305], [@bb0230], [@bb0290], [@bb0055], [@bb0045], [@bb0310], [@bb0225]). According to a previous study, six large deletions have been identified in 40 cases with syndromic and nonsyndromic RP ([@bb0100]). No large copy number variants were identified in another study using custom aCGH with high-density probes for genetic loci of *ABCA4*-associated disease ([@bb0330]) ([@bb0245]). Custom aCGH containing probes tiling *PCDH15* gene revealed large duplications in Usher patients ([@bb0180]). Up to date, a very restricted number of studies attempted to describe the genetic basis of Greek patients with these types of retinopathies ([@bb0285]).

In this study we sequenced the coding and adjoining intronic regions of the *ABCA4* gene and attempted to describe the phenotypic- genotypic correlation in unrelated Greek families, with autosomal recessive RP, autosomal recessive CORD and STGD1. Our results included known and novel variants. The pathogenicity of novel variants was investigated with segregation analysis in cases where family members were available and 200 control samples were screened for each novel variant. Further evaluation of each variant was attempted with the use of bioinformatic tools and in relation to the clinical phenotype.

2. Materials and methods {#s0010}
========================

2.1 Patients {#s0015}
------------

Our cohort included a total of 26 unrelated patients (n = 6 arRP, n = 10 STGD1 and n = 6 CORD) and 44 healthy first degree relatives (parents), all of Greek origin, who requested genetic testing by the Department of Medical Genetics, Medical School, University of Athens. Ophthalmologic evaluation of all individuals involved full ophthalmologic examination, fundus examination, fluorescein angiography, color vision testing, full-field electroretinograms (ff-ERG) and in some cases optical coherence tomography. All patients underwent electroretinogram tests following the ISCEV (International Society for Clinical Electrophysiology of Vision) standards. The diagnosis of STGD1 patients was based on the reduced central vision bilaterally and on the presence of "dark choroid" sign of fluorescein angiography. Most patients presented yellow flecks and atrophic lesions of choriocapillaris and RPE around the macula. The clinical features of autosomal recessive CORD patients included reduced visual acuity and color vision at the onset of the disease, followed by night blindness and loss of peripheral vision at later stages. The differential diagnosis between STGD1 and CORD patients was based on clinical examination and ff-ERG. Of note, ff-ERG of CORD patients showed loss of both cone and rod-mediated responses. Patients diagnosed with arRP initially presented difficulties at night vision while progressive loss of peripheral vision and visual acuity followed. The fundoscopic examination revealed bone spicule-like pigmentation extended from the peripheral retina to the macula. Patients\' scotopic ff-ERG was affected severely and before the reduction of photopic ff-ERG signs.

The genetic study was conducted in accordance with the principles of the Declaration of Helsinki and with the institutional guidelines defined by the ethics committee of the Faculty of Medicine of the National and Kapodistrian University of Athens. After the first session of genetic counseling, informed consent was obtained from all participants and a peripheral blood sample was collected.

2.2 DNA extraction {#s0020}
------------------

DNA was extracted from peripheral blood lymphocytes, automatically, with the use of MagAttract DNA Blood Mini M48 Kit (Qiagen GmBh, Hilden, Germany).

2.3 Mutation analysis {#s0025}
---------------------

Mutation screening of *ABCA4* involved direct sequencing of amplified exons. The 50 exons of *ABCA4* were amplified with M13-tagged specific primer sets. Flanking intronic sequences of approximately 100 bp of all exons, were also included. Public genome sequence databases were used for the design of PCR primers (NCBI: <http://www.ncbi.nlim.nih.gov>, ENSEMBL: <http://www.ensembl.org>). The primers were designed using Primer 3 ([@bb0235]). Primer sequences and PCR conditions are shown in [Supplementary Table 1](#ec0005){ref-type="supplementary-material"}. The PCR protocol used for the amplification of the specific fragments was based on the manufacturer\'s recommendations (HotStarTaq MasterMiKit, Qiagen, Hilden, Germany). A single-step enzymatic clean-up of PCR products was performed (ExoSAP-IT kit, Affymetrix, High Wycombe, United Kingdom), followed by sequencing reaction of all PCR products in a ABI3500 sequencer (Applied Biosystems, Inc., NY, USA) using the BigDye® Terminator v3.1/Sequencing Standard Kit (Applied Biosystems, Inc., NY, USA). The sequencing reaction was performed in both forward and reverse directions. Mutation nomenclature followed Human Genome Variation Society recommendations ([www.hgvs.org/mutnomen](http://www.hgvs.org/mutnomen){#ir0105}). DNA mutation numbering was based on the *ABCA4* Ref Seq mRNA sequence (GenBank accession number [NM_000350.1](ncbi-n:NM_000350.1){#ir0110}), with nucleotide + 1 being the A of the ATG translation initiation codon, while the corresponding amino acid residues were similarly numbered, with + 1 identifying the initial methionine of ABCA4 (GenBank ABCA4 Ref Seq NP_000341.2).

2.4 Mutation evaluation {#s0030}
-----------------------

We have attempted to evaluate the consequence of known and novel variants with family segregation analysis and *in silico* bioinformatic tools in combination with the clinical phenotype. The *in silico* tools used in this study are the following: SIFT ([@bb0150], [@bb0260]), PolyPhen-2 ([@bb0005]), PMut ([@bb0090]), PROVEAN ([@bb0050]), Human Splicing Finder (HSF3.0) ([@bb0075]) and Mutation Assessor ([@bb0220]). Frequency of each novel variant was investigated using 200 control samples, both males and females of Greek origin.

2.5 Array-comparative genome hybridization {#s0035}
------------------------------------------

In total, 25 patients diagnosed with RP, STGD1 and CORD and 2 unaffected family members, were analyzed for copy number variations (CNVs) using comparative genomic hybridization arrays (aCGH) as previously described ([@bb0035]). In brief, aCGH was performed using standard protocols with SurePrint G3 Human CGH 4x180K microarray platform (Agilent Technologies, Santa Clara, CA, USA). Each array contains approximately 180,000 60-mer oligonucleotide probes. Labeling was performed using the SureTag DNA labeling kit (Agilent technologies). The microarrays were hybridized in a rotisserie oven at 67 °C for 24 h according to manufacturer\'s recommendations. The arrays were scanned using an Agilent DNA microarray scanner (G2565CA, software version 4.8.4.1) and the spot intensities were measured using the Agilent Feature Extraction Software (version 10.7.3.1). Raw data were analyzed by Agilent Cytogenomics software (version 3.0.2.11). The cutoff for recording an alteration was ≥ 4 consecutive probes. For the interpretation of the results, the following databases were used: database of genomic variants (<http://projects.tcag.ca/variation/>), DECIPHER database (<http://www.sanger.ac.uk/PostGenomics/decipher/>), and the International Standards for Cytogenomic Arrays (<https://www.iscaconsortium.org>/).

3. Results {#s0040}
==========

3.1 Mutation and CNV detection {#s0045}
------------------------------

In total, mutations were detected in 86% (22/26) of the patients studied with STGD1, autosomal recessive RP and autosomal recessive CORD. The findings include 16 known mutations (12 missense, 1 nonsense and 3 splicing) and 2 novel genetic variants with unknown pathogenic significance. The patients\' clinical diagnosis, the identified mutations and bioinformatic results are shown in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}. Possible candidate genes associated with retinal dystrophies from aCGH results along with the clinical diagnosis are shown in [Table 5](#t0025){ref-type="table"}.

### 3.1.1 arRP cases {#s0050}

*ABCA4* mutations were identified in 6 arRP patients out of 10 that were studied. Only one mutation was found in 4 patients; 3 of them carried known pathogenic mutations and one of them carried the mutation p.His423Arg, which has previously been reported ([@bb0250], [@bb0300]) and has been registered as non pathogenic in the Retina International database (<http://www.retina-international.org>/). The p.Arg18Trp mutation was found in a female adult patient with arRP. This mutation has previously been described in patients with STGD1 ([@bb0105]). In addition, a p.Arg212Cys mutation was found in a male adult patient with arRP, along with c.6282 + 7G \> A, an intronic variant which has been reported as non-pathogenic ([@bb0300]). Known variations including p. Ser2255Ile and c.6282 + 7G \> A were found in two siblings; a 14-year-old boy and his 16-year-old sister, both affected with arRP ([@bb0300], [@bb0080]).

Results from aCGH analysis from a female patient with arRP indicated the existence of a 247 kb deletion (chromosome 1 position 216,090,502 to 216,337,490, hg19). The deletion, which was not found in her healthy daughter and grandson, included the *USH2A* gene, from intron 21 to intron 38. This patient also carried the mutation c.6282 + 7G \> A at intron 45 of *ABCA4.* A 79 kb deletion (chromosome 10, position 26,278,622 to 26,357,780, hg19), which involved the *MYO3A* gene was detected in a patient with arRP. This patient also carried p.Arg212Cys and c.6282 + 7G \> A mutations (exon 6 and intron 45 of *ABCA4*, respectively).

### 3.1.2 CORD cases {#s0055}

Six CORD patients, with autosomal recessive inheritance pattern, were screened for *ABCA4* mutations. Mutation at only one allele of the *ABCA4* gene was identified in those patients. Three patients carried the mutation p.His423Arg, which is considered non pathogenic as mentioned above. Another patient carried the p.Arg943Gln mutation which has already been reported in CORD patients ([@bb0135]). The p.Thr897Ile mutation was identified in another patient with autosomal recessive CORD. This mutation has been reported in previous studies in STGD1 patients ([@bb0300], [@bb0265], [@bb0095]). A novel intronic variation, c.161-5T \> C, at intron 2 was also found at a CORD patient in heterozygous state.

### 3.1.3 STGD1 cases {#s0060}

The p.Ala1598Asp and p.Gly1961Glu mutations were found in compound heterozygosity in the *ABCA4* gene in a male STGD1 patient. Thep.Leu541Pro and p.Ala1038Val mutations found in cis, according to family segregation analysis were identified in three STGD1 patients, along with other variations (p.Gly1961Glu and c.4352 + 1G \> A). A novel mutation, p. Leu1525Val, was found in exon 31 in a STGD1 patient. Three known genetic variations were identified in a female patient with STGD1 and in her brother, who was also affected; two missense mutations (p.Arg1108His and p.Ala854Thr in exons 22 and 16 respectively) and a mutation which affects the splicing process, c.5714 + 5G \> A in intron 40. Due to known variants that have been previously described in a small number of patients, both known and unknown variants were analyzed with bioinformatic tools. Specifically, Polyphen-2, SIFT, PROVEAN, Mutation Taster, Pmut and Mutation Assessor were employed for variations in coding sequences, whereas Human Splicing Finder was used for intronic variations. Detailed results from *in silico* analysis tools along with allele frequencies from 1000 Genomes Project ([www.1000genomes.org](http://www.1000genomes.org){#ir0155}) are shown in [Supplementary Table 2](#ec0010){ref-type="supplementary-material"}.

4. Discussion {#s0065}
=============

In the current study, we attempted to develop a potential sensitive and robust protocol for screening mutations in Greek patients diagnosed with STGD1, CORD and arRP. This protocol included the amplification and sequencing of all coding and flanking intronic regions of the *ABCA4* gene. A total of 18 genetic variations were detected, two of which, to the best of our knowledge have not been described elsewhere. In cases where no more than one mutation was detected, an alternative approach could be performed including screening of the entire *ABCA4* genomic locus for the identification of deep intronic variants. Previous studies have suggested that analysis of deep intronic *ABCA4* variants could facilitate the elucidation of the genetic causality underlying retinal dystrophies ([@bb0330], [@bb0165], [@bb0025]).

Despite the small number of cases screened, we found several mutations that frequently occur in other populations ([@bb0230], [@bb0040]), including p.Gly1961Glu and p.Ala1038Val. According to previous studies ([@bb0240], [@bb0155]) a combination of p.\[Leu541Pro; Ala1038Val\] and/or a truncating ABCA4 mutation resulted in an early disease onset. The \[p.Leu541Pro; p.Ala1038Val\] complex allele was identified in 4 STGD1 patients. Three of them carried the c.4352 + 1G \> A mutation at the second allele. They presented reduced visual acuity and rapid impairment of central vision with age of onset 4 to 10 years old. Therefore, our results are in line with the aforementioned studies.

A female STGD1 patient carried the \[p.Leu541Pro; p.Ala1038Val\] complex allele, which has been previously related to severe phenotype including rapid reduction in visual acuity in parallel with chorioretinal atrophy ([@bb0240]). An additional mutation, the p.Gly1961Gln, was detected on the other allele, which has been correlated with a milder end of the disease spectrum and with more severe phenotypes when patients carry additional *ABCA4* variants ([@bb0040]). Herein, the female patient presented a severe phenotype with reduced visual acuity and age of onset 20 years old. Multifocal ERG revealed significant reduction in macular function against the peripheral field of 30° and optic coherence tomography revealed diffused thinning of the neuroepithelium, particularly in the area of central fovea. Fluorescein angiography revealed punctate hyperfluorescence in the macula region bilaterally.

In addition, the p.Arg18Trp and p.Thr897Ile mutations were identified in patients with RP and CORD respectively, both with positive family history for autosomal recessive inheritance. Nevertheless, those mutations have been previously reported in STGD1 patients and may have a diverse impact on different patients, depending on the second allele ([@bb0115]).

The p. Leu1525Val affords a novel mutation detected in a STGD1 patient with age of onset seven years of age and remarkable worsening at the age of 14. More specifically, for this patient clinical examination revealed yellow-white flecks at the posterior pole as well as the presence of a mild destruction of foveal outer retinal structure. Notably, p.Leu1525Val was absent from all 200 control samples screened, while based on several *in silico* approaches, it was assessed as non pathogenic (SIFT, PROVEAN and PMut). Polyphen-2 assessed it as possibly damaging, whilst Mutation Taster characterized this mutation as disease causing, but with low score (32) ([Table 1](#t0005){ref-type="table"}). Furthermore, according to Mutation Assessor, this is a mutation with low impact on protein function but with score 1.9, close to the score of disease-associated variants. HSF3.0 revealed that this nucleotide substitution may affect the splicing process by activating an exonic cryptic donor site and by altering an exonic splicing enhancer site. This mutation probably contributed to the disease phenotype in association with other gene mutations, or at positions of *ABCA4* that were not analyzed, such as deep intronic sequences. No pathogenic CNVs were identified with aCGH analysis for this patient. It is generally accepted that the use of *in silico* tools could contribute to the characterization of novel variants. In the current study results from bioinformatic tools were contradicting, making their contribution inadequate. Subsequently a potential alternative could lead to functional studies, with all the related issues arising from the nature of the affected tissue.

The novel variant c.161-5T \> C, identified in intron 2 of a CORD patient, was also absent in 200 control samples from Greek individuals. No significant splicing motif alteration was predicted by HSF3.0. Further functional studies need to be done in order to clarify the role of these alterations in the splicing process. All mutations were found in heterozygosity, indicating the huge allelic heterogeneity of *ABCA4* and the complex haplotypes of patients with these retinal diseases. This fact makes genetic counseling and prognosis even more difficult.

We also performed array-comparative genomic hybridization (aCGH), for the detection of large deletions or duplications, on patients with one known *ABCA4* mutation identified with Sanger sequencing and on patients with no *ABCA4* mutations. Array-CGH revealed large deletions in two out of the 25 cases studied. The first patient was diagnosed with nonsyndromic, autosomal recessive RP and was found to carry a heterozygous 247 kb deletion at 1q41, resulting in partial deletion (intron 21 to intron 38) of the *USH2A* gene. This deletion was not identified in the patient\'s healthy daughter and grandson. Partial deletion of *USH2A* has been previously described in only one patient with nonsyndromic RP ([@bb0100]). Specific point mutations in *USH2A* have also been related to nonsyndromic autosomal recessive RP ([@bb0170], [@bb0110], [@bb0205], [@bb0315]). Partial *USH2A* deletions have been reported only in Usher syndrome patients in several studies so far ([@bb0145], [@bb0275], [@bb0255]). Therefore, taking into consideration the family segregation analysis and previous studies, we conclude that the 247 kb deletion at 1q41 is the possible cause of the disease.

In the second case, a male patient with nonsyndromic autosomal recessive RP, a 79 kb deletion at 10p12.1, which involved the *MYO3A* gene, was identified. The *MYO3A* gene codes a highly conserved protein, myosin VIIA, which is expressed mainly in retina and cochlea ([@bb0175], [@bb0295]). Sequencing variants of *MYO3A* have been associated with autosomal dominant and recessive hearing impairment ([@bb0185], [@bb0190]) and with Usher syndrome in patients from diverse origins ([@bb0270], [@bb0215], [@bb0125], [@bb0160]). No family segregation analysis was possible for the patient of our cohort, who also carried mutations p.Arg212Cys and c.6282 + 7G \> A (exon 6 and intron 45 of *ABCA4* respectively). The contribution of the partial heterozygous deletion of *MYO3A* to the pathogenesis of the disease cannot be definitely supported. Expansion of genetic testing to larger cohorts will allow the evaluation of novel findings.

The identification of the genetic causes that lead to the clinical phenotype of hereditary retinal dystrophies, such as STGD1, arRP or CORD is very important for the accurate clinical diagnosis, prognosis and genetic counseling and eventually could also contribute to the therapeutic approach. In the current study, the suggested mutation screening protocol in combination with segregation analyses, patients\' clinical data and *in silico* approaches, seemed to be valuable, in Greek patients carrying more than one mutation and diagnosed with STGD1, arRP or autosomal recessive CORD. In Greek patients with no identified *ABCA4* mutation(s) entire screening of the specific genomic locus for the identification of deep intronic variants or next generation sequencing is necessary.

The following are the supplementary data related to this article.Supplementary Table 1Primers' details for all coding and flanking intronic sequences for *ABCA4*.Supplementary Table 2*In silico* mutation evaluation along with data from 1000 Genomes Project.
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###### 

Summary of mutation details and *in silico* analysis

  Variation ID   Amino acid change   Nucleotide change   Exon/Intron   PolyPhen-2           SIFT          PROVEAN           Mutation taster    Pmut        Mutation Assessor   HSF
  -------------- ------------------- ------------------- ------------- -------------------- ------------- ----------------- ------------------ ----------- ------------------- ------------------------------------------------------
  CM980003       p.Arg18Trp          c.52C \> T          1             Prob. Dam. (1)       Dam. (0)      Del. (− 6314)     Dis. Caus. (101)   Path. (7)   Medium (2.92)       N/A
  CM015072       p.His423Arg         c.1268 A \> G       10            Benign (0)           T (0.39)      Neut. (2.141)     Polym. (29)        Neut. (5)   Neutral (− 2.255)   N/A
  CM003575       p.Thr897Ile         c.2690C \> T        18            Benign (0.054)       T (0.18)      Neut. (− 1.659)   Dis. Caus. (89)    Path. (5)   Low (1.1)           N/A
  CM024629       p.Arg943Gln         c.2828G \> A        19            Benign (0.010)       T (0.16)      Neut. (− 0.999)   Polym. (43)        Path. (4)   Low (0.855)         N/A
  Novel          --                  c.161-5T \> C       int2          N/A                  N/A           N/A               N/A                N/A         N/A                 Disruption of motifs for SRp40 protein
  CM980004       p.Arg212Cys         c.634C \> T         6             Prob. Dam. (1)       Dam. (0)      Del. (− 3.906)    Dis. Caus. (180)   Path. (2)   Medium (2.395)      N/A
  CS003628       --                  c.6282 + 7G \> A    int45         N/A                  N/A           N/A               N/A                N/A         N/A                 Disruption of ESE motifs
  CM023000       p.Ser2255Ile        c.6764G \> T        49            Benign (0)           T (0.12)      Neut. (− 0.989)   Polym. (142)       Path. (1)   Neutral (0.255)     N/A
  CM003386       p.Ala1598Asp        c.4793C \> A        34            Poss. Dam. (0.870)   Dam. (0.01)   Neut. (− 2.285)   Dis. Caus. (126)   Path. (8)   Medium (2,33)       N/A
  CM970016       p.Gly1961Glu        c.5882G \> A        42            Prob. Dam. (1)       Dam. (0)      Del. (− 6.589)    Dis. Caus. (98)    Path. (8)   Neutral (− 0.545)   N/A
  CM990022       p.Leu541Pro         c.1622 T \> C       12            Prob. Dam. (0.994)   Dam. (0,01)   Del. (− 5.853)    Dis. Caus. (98)    Neut. (6)   Medium (3,145)      N/A
  CM970006       p.Ala1038Val        c.3113C \> T        21            Benign (0.009)       T (1)         Neut. (− 0.235)   Dis. Caus. (64)    Path. (2)   Neutral (0.625)     N/A
  CS982057       --                  c.5714 + 5G \> A    int40         N/A                  N/A           N/A               N/A                N/A         N/A                 Donor splice site affected
  CD003502       p.Val1973X          c.5917delT          43            N/A                  N/A           Del. (− 4.527)    Dis. Caus. (6)     N/A         N/A                 N/A
  Novel          p.Leu1525Val        c.4573C \> G        31            Poss. Dam. (0.5)     T (0.09)      Neut. (− 2.287)   Dis. Caus. (32)    Neut. (2)   Low (1.9)           N/A
  CS099669       --                  c.4352 + 1G \> A    int29         N/A                  N/A           N/A               N/A                N/A         N/A                 Donor splice site affected, disruption of ESE motifs
  CM015083       p.Arg1108His        c.3323G \> A        22            Prob. dam. (0.984)   Dam. (0)      Del. (− 4.341)    Dis. Caus. (29)    Path. (7)   Low (1.915)         N/A
  CM015077       p.Ala854Thr         c.2560G \> A        16            Benign (0.119)       T (1)         Neut. (0.694)     Dis. Caus. (58)    Neut. (3)   Neutral (0.545)     N/A

Abbreviations: N/A: non-applicable, PolyPhen-2: Polymorphism Phenotyping v2 (<http://genetics.bwh.harvard.edu/pph2/>), SIFT: Sorting Intolerant From Tolerant (<http://sift.jcvi.org>/), PROVEAN: Protein Variation Effect Analyzer (<http://provean.jcvi.org/index.php>), Mutation taster: <http://www.mutationtaster.org>/, Pmut: <http://mmb2.pcb.ub.es:8080/PMut/>, Mutation Assessor: <http://mutationassessor.org>/, HSF: Human Splicing Finder (<http://www.umd.be/HSF3/HSF.html>), Prob. Dam: probably damaging, Poss. Dam: possibly damaging, Dam: damaging, T: tolerated, Del: deleterious, Dis Caus: disease causing, Polym: polymorphism, Path: pathological, Neut: neutral, ESE: exonic splicing enhancer.

###### 

Summary of clinical phenotype and genotype for each patient

  Patient    Sex            Clinical diagnosis   Inheritance manner   Variation ID   Amino acid change   Nucleotide change
  ---------- -------------- -------------------- -------------------- -------------- ------------------- -------------------
  1          F              RP                   AR                   CM980003       p.Arg18Trp          c.52C \> T
  2          F              CORD                 AR                   CM015072       p.His423Arg         c.1268 A \> G
  3          F              STGD1                AR                   CM015072       p.His423Arg         c.1268 A \> G
  4          F              CORD                 AR                   CM015072       p.His423Arg         c.1268 A \> G
  5          F              CORD                 AR                   CM003575       p.Thr897Ile         c.2690C \> T
  6          F              CORD                 AR                   CM024629       p.Arg943Gln         c.2828G \> A
  7          M              STGD1                AR                   CD003502       p.Val1973X          c.5917delG
  8          M              CORD                 AR                   novel          --                  c.161-5T \> C
  9          M              RP                   AR                   CM980004       p.Arg212Cys         c.634C \> T
  CS003628   --             c.6282 + 7G \> A                                                             
  10         M              RP                   AR                   CM015072       p.His423Arg         c.1268 A \> G
  11         F              RP                   AR                   CS003628       --                  c.6282 + 7G \> A
  12         M              CORD                 AR                   CM015072       p.His423Arg         c.1268 A \> G
  13         F              RP                   AR                   CS003628       --                  c.6282 + 7G \> A
  CM023000   p.Ser2255Ile   c.6764G \> T                                                                 
  14         M              RP                   AR                   CS003628       --                  c.6282 + 7G \> A
  15         M              STGD1                AR                   CM003386       p.Ala1598Asp        c.4793C \> A
  CM970016   p.Gly1961Glu   c.5882G \> A                                                                 
  16         F              STGD1                AR                   CM990022       p.Leu541Pro         c.1622 T \> C
  CM970006   p.Ala1038Val   c.3113C \> T                                                                 
  CM970016   p.Gly1961Glu   c.5882G \> A                                                                 
  17         F              STGD1                AR                   CS982057       --                  c.5714 + 5G \> A
  CD003502   p.Val1973X     c.5917delT                                                                   
  18         M              STGD1                AR                   novel          p.Leu1525Val        c.4573C \> G
  19         F              STGD1                AR                   CM990022       p.Leu541Pro         c.1622 T \> C
  CM970006   p.Ala1038Val   c.3113C \> T                                                                 
  CS099669   --             c.4352 + 1G \> A                                                             
  20         M              STGD1                AR                   CM990022       p.Leu541Pro         c.1622 T \> C
  CM970006   p.Ala1038Val   c.3113C \> T                                                                 
  CS099669   --             c.4352 + 1G \> A                                                             
  21         M              STGD1                AR                   CM990022       p.Leu541Pro         c.1622 T \> C
  CM970006   p.Ala1038Val   c.3113C \> T                                                                 
  CS099669   --             c.4352 + 1G \> A                                                             
  22         F              STGD1                AR                   CM015083       p.Arg1108His        c.3323G \> A
  CM015072   p.His423Arg    c.1268 A \> G                                                                
  CM015077   p.Ala854Thr    c.2560G \> A                                                                 
  CS982057   --             c.5714 + 5 \> A                                                              

Abbreviations: M: male, F: female, RP: Retinitis Pigmentosa, CORD: Cone-Rod dystrophy, STGD1: Stargardt\'s disease, AR: autosomal recessive.

###### 

Clinical information for patients which were biallelic for *ABCA4* following segregation analyses

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient No   Allele 1                       Allele 2           Clinical diagnosis   Age   Age of onset   BCVA OD   BCVA OS   ff-ERG/cone   ff-ERG/rod   mERG                      Additional clinical characteristics
  ------------ ------------------------------ ------------------ -------------------- ----- -------------- --------- --------- ------------- ------------ ------------------------- --------------------------------------------------
  9            c.643C \> T                    c.6282 + 7G \> A   arRP                 40    18             0.02      0.04      ↓             ↓↓           n/a                       night blindness, narrowed retinal vessels, bone\
                                                                                                                                                                                    spicule-like pigmentation at periphery

  13           c.6282 + 7G \> A               c.6764G \> T       arRP                 35    14             0.04      0.06      ↓             ↓            ↓ at macula bilaterally   Night blindness, bone\
                                                                                                                                                                                    spicule-like pigmentation at periphery

  15           c.4793C \> A                   c.5882G \> A       STGD1                30    12             0.14      0.16      ↓             N            n/a                       Small central scotomas within 30--40°

  16           c.\[1622 T \> C;3113C \> T\]   c.5882G \> A       STGD1                31    20             0.16      0.18      N             N            ↓ at macula bilaterally   Small central scotoma

  17           c.5714 + 5G \> A               c.5917delT         STGD1                38    18             0.08      0.1       ↓             N            n/a                       Small central scotoma

  19           c.\[1622 T \> C;3113C \> T\]   c.4352 + 1G \> A   STGD1                12    10             0.04      0.04      ↓             N            n/a                       Dark choroid sign on IVFA

  20           c.\[1622 T \> C;3113C \> T\]   c.4352 + 1G \> A   STGD1                18    4              0.02      0.02      ↓             N            ↓ at macula bilaterally   Dark choroid sign on IVFA

  21           c.\[1622 T \> C;3113C \> T\]   c.4352 + 1G \> A   STGD1                11    7              0.04      0.04      ↓             N            n/a                       Dark choroid sign on IVFA

  22           c.3323G \> A                   c.5714 + 5G \> A   STGD1                35    18             0.14      0.12      ↓             N            ↓ at macula bilaterally   Dark choroid sign on IVFA
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: BCVA: best-corrected visual acuity, OD: right eye, OS: left eye, ff-ERG: full-field electroretinogram, mERG: multifocal electroretinogram, ↓ reduced, ↓↓ severely reduced, IVFA: intravenous fluorescein angiography, n/a not available.

###### 

Summary of details of novel mutations and *in silico* analysis

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Novel mutations and *in silico* analysis                                                                                                               
  ------------------------------------------ --------------- ------ ----------------- ---------- ----------- ----------------- ------------- ----------- -----------------------------------------------------------------------------------------------------------------
  p.Leu1525Val                               c.4573C \> G    31     Pos. Dam. (0.5)   T (0.09)   Neutral\    Dis. Caus. (32)   Neutral (2)   Low (1.9)   Activation of an exonic cryptic donor site. Alteration of an exonic ESE site. Potential alteration of splicing.
                                                                                                 (− 2.287)                                               

  --                                         c.161-5T \> C   int2   N/A               N/A        N/A         N/A               N/A           N/A         No significant splicing motif alteration detected.
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: N/A: non-applicable, PolyPhen-2: Polymorphism Phenotyping v2 (<http://genetics.bwh.harvard.edu/pph2/>), SIFT: Sorting Intolerant From Tolerant (<http://sift.jcvi.org>/), PROVEAN: Protein Variation Effect Analyzer (<http://provean.jcvi.org/index.php>), Mutation taster: <http://www.mutationtaster.org>/, Pmut: <http://mmb2.pcb.ub.es:8080/PMut/>, Mutation Assessor: <http://mutationassessor.org>/, HSF: Human Splicing Finder (<http://www.umd.be/HSF3/HSF.html>), Poss. Dam: possibly damaging, Dam: damaging, T: tolerated, Dis Caus: disease causing, ESE: exonic splicing enhancer.

###### 

Summary of clinically significant CNV findings

  Submicroscopic rearrangements (CNVs) in our patients with retinal dystrophy                                                  
  ----------------------------------------------------------------------------- ------ --------------------- ----------------- ----------------------------------------------------
  9                                                                             arRP   Del 10p12.1 (0,079)   *MYO3A*(606808)   p.Arg212Cys (exon 6), c.6282 + 7G \> A (intron 45)
  11                                                                            arRP   Del 1q41 (0,247)      *USH2A*(608400)   c.6282 + 7G \> A (intron 45)

Abbreviations: RD: retinal dystrophies, arRP: autosomal recessive retinitis pigmentosa, CNVs: copy number variations.
